Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02306473 · ClinicalTrials.gov registry record · Early Phase 1

The Leaky Lung Test

A Early Phase 1 study of Asthma and Allergy, sponsored by University of Rochester.

Completed
Registry status
Early Phase 1
Development phase
100
Enrollment target
1
Study location

NCT02306473 is a Early Phase 1 study of Asthma and Allergy that has completed, run by University of Rochester. The registered enrollment target is 100 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02306473, a Early Phase 1 study of Asthma and Allergy, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Early Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial designed to test the hypothesis that measuring the absorption and excretion of inhaled mannitol will provide a clinically useful marker of airway epithelial permeability in asthma.

Interventions

  • DRUG Mannitol

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2015-10
Est. Completion 2017-12-01
Phase Early Phase 1

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT02306473

The ClinicalTrials.gov registry entry for NCT02306473 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Mannitol is the first listed.

NCT02306473 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02306473 about?

NCT02306473 is a clinical study titled "The Leaky Lung Test". This is a clinical trial designed to test the hypothesis that measuring the absorption and excretion of inhaled mannitol will provide a clinically useful marker of airway epithelial permeability in asthma.

What is the current status of trial NCT02306473?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2015-10. Estimated completion is 2017-12-01.

What conditions does trial NCT02306473 study?

This clinical trial studies the following conditions: Asthma, Allergy, Lung Diseases, Obstructive, Reactive Airway Disease.

What interventions are being tested in trial NCT02306473?

The interventions under investigation include: Mannitol (DRUG).

Who is sponsoring clinical trial NCT02306473?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02306473 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.